Finance

Beta
Lists
SN:LON
Smith & Nephew plc
GBX 1,151.00
+1.63%
(+18.50) 1D
Jun 5, 6:55:46 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for SN...
Open
GBX 1,144.00
High
GBX 1,156.00
Low
GBX 1,143.50
Mkt. cap
12.82B
Avg. vol.
3.09M
Volume
2.79M
Dividend
2.52%
Quarterly dividend
GBX 7.26
Ex-dividend date
Mar 26, 2026
P/E ratio
21.58
52-wk high
GBX 1,441.50
52-wk low
GBX 1,050.00
EPS
GBX 0.53
Shares outstanding
850.21M
No. of employees
17K
Open
GBX 1,144.00
High
GBX 1,156.00
Low
GBX 1,143.50
Mkt. cap
12.82B
Avg. vol.
3.09M
Volume
2.79M
Dividend
2.52%
Quarterly dividend
GBX 7.26
Ex-dividend date
Mar 26, 2026
P/E ratio
21.58
52-wk high
GBX 1,441.50
52-wk low
GBX 1,050.00
EPS
GBX 0.53
Shares outstanding
850.21M
No. of employees
17K
Analyst outlook
Analyst Ratings
Based on 7 analysts giving stock ratings to SN in the past 3 months
Buy
Buy
4
Hold
3
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for SN in the last 3 months.
Highest
Current GBX 1,151.00
GBX 1,600.00 (+39.01%)
Average
GBX 1,438.43 (+24.97%)
Lowest
GBX 1,300.00 (+12.95%)
News stories
From sources across the web
Profile
Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index. Wikipedia
About Smith & Nephew plc
CEODeepak Nath
Employees17K
Founded1856
Headquarters-
SectorMedical device
Websitesmith-nephew.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.48B
1.48B
1.60B
1.60B
Cost of goods sold
435.00M
435.00M
543.50M
543.50M
Cost of revenue
435.00M
435.00M
543.50M
543.50M
Research and development expenses
71.50M
71.50M
75.50M
75.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
759.50M
759.50M
758.50M
758.50M
Operating expense
831.00M
831.00M
834.00M
834.00M
Total operating expenses
1.27B
1.27B
1.38B
1.38B
Operating income
214.50M
214.50M
224.00M
224.00M
Other non operating income
-6.00M
-6.00M
1.00M
1.00M
EBT including unusual items
181.00M
181.00M
208.50M
208.50M
EBT excluding unusual items
181.00M
181.00M
253.00M
253.00M
Income tax expense
34.50M
34.50M
42.50M
42.50M
Effective tax rate
19.06%
19.06%
20.38%
20.38%
Other operating expenses
-
-
-
-
Net income
146.50M
146.50M
166.00M
166.00M
Net profit margin
9.90%
9.90%
10.37%
10.37%
Earnings per share
-
-
-
-
Interest and investment income
7.50M
7.50M
6.50M
6.50M
Interest expense
-34.50M
-34.50M
-35.50M
-35.50M
Net interest expenses
-27.00M
-27.00M
-29.00M
-29.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
351.00M
351.00M
317.00M
317.00M
Gain or loss from assets sale
5.50M
5.50M
6.00M
6.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer